PLCB2

Across TCGA pan-cancer cohorts, PLCB2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLCB2 data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher PLCB2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLCB2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

COAD, PDAC, and HNSC are the cancer types where PLCB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Tertile	All	0.819	1.000	.015	96	view →
PDAC	DFS	Median	III,IV	0.539	0.173	.005	12	view →
HNSC	OS	Median	II,III,IV	0.952	1.000	.016	4	view →
LUAD	DFS	Quartile	III,IV	0.378	0.683	.044	3	view →
GBM	OS	Tertile	All	0.455	0.660	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLCB2–COAD (DFS)

Open the COAD breakdown →